Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from McGill University and the University of Oxford carried out a systematic review and meta-analysis of the best existing evidence and analysed 23,317 individuals (from 11 international studies) to see whether use of cannabis in young people is associated with depression, anxiety and suicidality in early adulthood.

Teenager curled up in a ball leaning against lockers in a school with their head in their arms.

They found that cannabis use among adolescents is associated with a significant increased risk of depression and suicidality in adulthood (not anxiety). While the individual-level risk was found to be modest, the widespread use of the drug by young people makes the scale of the risk much more serious.

Professor Andrea Cipriani, NIHR Research Professor of Psychiatry at the University of Oxford, said: "Our findings about depression and suicidality are very relevant for clinical practice and public health. Although the size of the negative effects of cannabis can vary between individual adolescents and it is not possible to predict the exact risk for each teenager, the widespread use of cannabis among the young generations makes it an important public health issue."

Regular use during adolescence is associated with lower achievement at school, addiction, psychosis and neuropsychological decline, increased risk of motor vehicle crashes, as well as the respiratory problems that are associated with smoking.
Professor Andrea Cipriani. 

Similar stories

Study sheds new light on how ketamine may act rapidly in the human brain

Researchers have identified a brain mechanism that could help explain ketamine’s unusually rapid antidepressant effects, providing new clues for the development of faster and potentially more targeted treatments for depression.

Semaglutide associated with fewer cognitive problems in people with mental illness

Semaglutide, widely used to treat diabetes and obesity, was associated with fewer cognitive signs and symptoms in people with psychiatric disorders, according to a new study led by researchers at the University of Oxford.

Infections linked to higher risk of brain and mental health conditions for up to two years

A large study of more than 1 million matched patient pairs finds that serious infections across the body are followed by increased risks of psychiatric and neurological diagnoses, especially in adults

Salsa classes shown to reduce depressive symptoms in young adults

A new trial led by the University of Oxford suggests it may offer a promising, accessible addition to youth wellbeing support.

The 50th Anniversary of the Oxford Self-harm Monitoring System

Influential and impactful Oxford Self-harm Monitoring System had been in place, and continuously funded, for 50 years.

Better cognition tied to higher relapse risk after depression remission

Oxford and Birmingham study with more than 3,700 UK participants challenges idea that cognitive decline would be associated with relapse risk

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.